Skip to main content
. 2021 May 29;16:241. doi: 10.1186/s13023-021-01880-8

Table 1.

Overall incidence and prevalence rates of MPS in United States (1995–2015) based on the National MPS Society membership

MPS type Number of patients Percentage of all MPS (%) Incidence per 100,000 Prevalence per 1,000,000
MPS I (Hurler Syndrome) 207 26.23 0.26 0.70
MPS II (Hunter Syndrome) 207 26.23 0.26 0.70
MPS III (Sanfilippo Syndrome) 210 26.60 0.26 0.71
 Type A 153 19.40 0.19 0.52
 Type B 40 5.10 0.05 0.14
 Type C 12 1.50 0.015 0.04
 Type D 0 0.00 0 0
MPS IV (Morquio Syndrome) 113 14.32 0.14 0.38
 Type Aa 87 11.00 0.11 0.29
 Type B 3 0.40 0.004 0.01
MPS VI (Maroteaux-Lamy Syndrome) 31 3.92 0.04 0.11
MPS VIIb (Sly Syndrome) 21 2.70 0.027 0.07
MPS IX (Hyaluronidase deficiency) 0 0.00 0 0
All Mucopolysaccharidoses 789 100.00 0.98 2.67

Some patients are reported as MPS III or IV while there is no information on the sub-type

aBased on information from the MPS IVA International registry [7]

bBased on information provided by Ultragenyx Pharmaceuticals